The Efficacy and Safety of tDCS in Patients With Mild Dementia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluated the effectiveness and safety of improving Mild Dementia by applying tDCS for 26 weeks to patients with Mild Dementia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Safety of tDCS in Patients With Mild to Moderate Major Depressive Disorder

NCT04720040

Depression

COMPLETED NA

Study of tDCS for Mild Cognitive Impairment

NCT02320890

Mild Cognitive Impairment

COMPLETED NA

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

NCT06088121

Alzheimer's Disease Dementia Brain Diseases +5 more

RECRUITING NA

Network-guided TMS in Early Alzheimer's Disease

NCT04549155

Mild Cognitive Impairment

COMPLETED NA

Transcranial Magnetic Stimulation in Mild Cognitive Impairment and Alzheimer Disease

NCT04771845

Alzheimer Disease Mild Cognitive Impairment

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients received tDCS for 30 minutes with an intensity of 1.5 to 2 mA. tDCS was applied over the left (anode) and right (cathode) dorsolateral prefrontal cortex (DLPFC) 5\~7 times a week and they were evaluated every 26weeks through questionnaires.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham Stimulation

Group Type SHAM_COMPARATOR

Sham stimulation using YMS-201B

Intervention Type DEVICE

Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Real Stimulation (Active)

transcranial Direct Current Stimulation (tDCS) application 5 \~7 days a week for 26 weeks

Group Type EXPERIMENTAL

YMS-201B (Device: Mind STIM)

Intervention Type DEVICE

transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

YMS-201B (Device: Mind STIM)

transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Intervention Type DEVICE

Sham stimulation using YMS-201B

Sham stimulation; only 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 55 to 90 years old.
* Those diagnosed with dementia (major neurocognitive disorder, neurocognitive disorder) according to the criteria of Diagnostic and Statistical Manual (DSM-V) or The International Statistical Classification of Diseases and Related Health Provisions (ICD-10).
* Patients with mild dementia with a MMSE (Mini Mental State Examination) score of 18 points or more and less than 26 points) and less than 26 points.
* Person who has a clinical dementia rating (CDR) global score of 0.5 or 1.0, while CDR-SOB (Sum of Boxes) score satisfies 0.5 to 4.0 points 2)
* Acetylcholinease inhibitors (ACEI) and NMDA receptor inhibitors are those with the same usage and capacity for at least 3 months from the date of screening.

\* Patients who are taking drugs for cognitive functional treatment (e.g., pregabalin, gabapentincholinephocerate, etc.) other than acetylcholine inhibitor and NMDA receptor antagonist, and drugs for chronic diseases including hypertension, diabetes, hyperlipidemia, thyroid disease, etc.
* A person who can read and understand the subject's explanation and consent form, and who can speak at the level of ability to respond to questionnaires.
* A person who can be accompanied by a guardian when visiting a research institute during the clinical trial process, and who can help the guardian to proceed with the clinical trial process normally.
* A person who voluntarily decided to participate in this clinical trial and agreed in writing to the subject's written consent, who can participate in the pre-clinical trial period.

Exclusion Criteria

* A person with a history of uniaxial psychiatric diseases including intellectual disability, schizophrenia, alcoholism, and bipolar disorder in the past.
* A person who has a history of convulsions within 5 years of screening.
* Those who have been diagnosed with severe cerebrovascular stenosis, subdural hemorrhage, brain tumor, and brain abscess through transient ischemic attack, stroke or MRI within one year from the screening date and are considered inappropriate for participation in this test.
* A person who has cerebral damage due to trauma, ischemia, hypoxia, etc.
* A person who has been hospitalized for mental or emotional problems within 5 years of screening.
* A person who abused drugs within 5 years of screening.
* A person who received treatment for alcoholism within 5 years of screening.
* A person who can't read even with glasses on due to poor eyesight.
* A person who can't understand a conversation because of hearing impairment even when wearing a hearing aid.
* A person who has difficulty breathing when sitting still.
* A person who attempted suicide within 6 months from the screening date.
* A person who is judged to have a problem with brain waves and direct current stimulation electrodes due to deformities, inflammatory reactions, or other dermatological problems in the scalp.
* A person who is judged to have other reasons for prohibition of use of tDCS medical devices (e.g., when a metal plate is inserted into the head, etc.).
* Those who participated in other clinical trials within 30 days of screening.
* Among female subjects who are likely to be pregnant, those who disagree with contraception\* in a medically permitted manner during this clinical trial period.

\*Medically permitted contraceptive methods: condoms, oral contraceptives that last at least 3 months, injections or insertion contraceptives, etc. are used, and intrauterine contraceptives are installed, etc.
* Pregnant women or lactating women.
* In addition to the above, a person in charge of the test or a person in charge has a clinical significance that is medically judged and deemed inappropriate for this test.

Minimum Eligible Age

55 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No